非洲四国HIV感染者治疗前与获得性耐药研究
在乌干达、肯尼亚、坦桑尼亚和尼日利亚12家诊所,对972名HIV-1 RNA>1000 copies/mL的成人进行耐药检测。未治疗者筛查耐药突变流行率11.0%,治疗失败者NNRTI突变83.6%、NRTI突变67.8%。部分已耐药者仍在服用无效药物。
要点
- 未治疗者中WHO监测耐药突变流行率11.0%,以NNRTI突变为主。
- 治疗失败者中NNRTI突变83.6%、NRTI突变67.8%,耐药负担高。
- 部分对依非韦伦/拉米夫定或替诺福韦/拉米夫定耐药者仍在服用相应药物。
核心结论
- 治疗失败者携带高负担HIV耐药,可能限制标准化一线和二线方案疗效。
- 强调依从性咨询而延迟换药可能促进耐药,应重新考虑该策略。
研究设计与样本
- 非洲队列研究(AFRICOS),2013年1月至2019年4月在四国12家诊所纳入HIV-1 RNA>1000 copies/mL的成人。
- 共972人接受耐药检测,中位年龄35.7岁,中位CD4 295 cells/mm3。
- 使用Stanford HIVDB 8.8和SmartGene IDNS软件计算耐药评分及主要突变。
主要发现
- 801名未治疗者中,WHO监测耐药突变流行率11.0%,NNRTI突变8.2%,NRTI突变4.7%,PI突变0.4%。
- 171名治疗失败者中,NNRTI突变83.6%,NRTI突变67.8%,PI突变1.8%。
- 90名对依非韦伦和拉米夫定均耐药者中,33人(36.7%)仍在服用这两药。
- 10名对替诺福韦和拉米夫定均耐药者中,8人(80.0%)仍在服用这两药。
临床怎么用
- 对病毒学失败者应尽早评估耐药并调整方案,避免继续使用已耐药药物。
- 在资源有限地区需加强耐药监测,指导一线和二线方案选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging HIV drug resistance (HIVDR) could jeopardize the success of standardized HIV management protocols in resource-limited settings. We characterized HIVDR among antiretroviral therapy (ART)-naive and experienced participants in the African Cohort Study (AFRICOS). METHODS: From January 2013 to April 2019, adults with HIV-1 RNA >1000 copies/mL underwent ART history review and HIVDR testing upon enrollment at 12 clinics in Uganda, Kenya, Tanzania, and Nigeria. We calculated resistance scores for specific drugs and tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) using Stanford HIVDB 8.8 and SmartGene IDNS software. For ART-naive participants, World Health Organization surveillance drug resistance mutations (SDRMs) were noted. RESULTS: HIVDR testing was performed on 972 participants with median age 35.7 (interquartile range [IQR] 29.7-42.7) years and median CD4 295 (IQR 148-478) cells/mm3. Among 801 ART-naive participants, the prevalence of SDRMs was 11.0%, NNRTI mutations 8.2%, NRTI mutations 4.7%, and PI mutations 0.4%. Among 171 viremic ART-experienced participants, NNRTI mutation prevalence was 83.6%, NRTI 67.8%, and PI 1.8%. There were 90 ART-experienced participants with resistance to both efavirenz and lamivudine, 33 (36.7%) of whom were still prescribed these drugs. There were 10 with resistance to both tenofovir and lamivudine, 8 (80.0%) of whom were prescribed these drugs. CONCLUSIONS: Participants on failing ART regimens had a high burden of HIVDR that potentially limited the efficacy of standardized first- and second-line regimens. Management strategies that emphasize adherence counseling while delaying ART switch may promote drug resistance and should be reconsidered.
引用
- Crowell TA, Danboise B, Parikh A, et al. Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries. Clin Infect Dis. 2021. PMID: 32785695. doi:10.1093/cid/ciaa1161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。